Obesity and cancer: Local and systemic mechanisms

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 297-309

  Iyengar, Neil M ^a,b,c   Hudis, Clifford A ^a,b   Dannenberg, Andrew J ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

adipocytes; adipose tissue; body mass index; cancer risk; inflammation; insulin resistance; macrophages; metabolic syndrome

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANDROGEN; ESTROGEN; INSULIN; LEPTIN; STEROID HORMONE; CYTOKINE; SOMATOMEDIN C;

ADIPOCYTE; ADIPOSE TISSUE; ARTICLE; CARCINOGENESIS; HUMAN; HYPERINSULINEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC DISORDER; NEOPLASM; OBESITY; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WHITE ADIPOSE TISSUE; METABOLISM;

ADIPOKINES; ADIPOSE TISSUE; ANDROGENS; CYTOKINES; ESTROGENS; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; LIPID METABOLISM; NEOPLASMS; OBESITY;

EID: 84921345437     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-050913-022228     Document Type: Article

References (100)

1. Levi J, Segal LM, St. Laurent R, et al. 2012. F as in Fat: how obesity threatens America's future 2012. Trust for America's Health Rep. http://healthyamericans.org/report/100/
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. 2010. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303:235-41
3. Calle EE, Kaaks R. 2004. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4:579-91
4. van Kruijsdijk RC, van der Wall E, Visseren FL. 2009. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol. Biomark. Prev. 18:2569-78
5. Calle EE, RodriguezC, Walker-Thurmond K, ThunMJ. 2003. Overweight, obesity, andmortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348:1625-38
6. Iyengar NM, Morris PG, Hudis CA, Dannenberg AJ. 2013. Obesity, inflammation, and breast cancer. In Obesity, Inflammation, and Cancer, ed. AJ Dannenberg, NA Berger, pp. 181-217. New York: Springer
7. Yoon HH, Lewis MA, Shi Q, et al. 2011. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J. Clin. Oncol. 29:4561-67
8. IyengarNM, HudisCA, Dannenberg AJ. 2013. Obesity and inflammation: new insights into breast cancer development and progression. In American Society of Clinical Oncology 2013 Educational Book, pp. 46-51. Alexandria, VA: Am. Soc. Clin. Oncol.
9. Iyengar NM, Kochhar A, Morris PG, et al. 2014. Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. Cancer 120:983-91
10. Berger NA. 2014. Obesity-Associated gastrointestinal tract cancer: from beginning to end. Cancer 120:935-39
11. Guilherme A, Virbasius JV, Puri V, Czech MP. 2008. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9:367-77
12. Hursting SD, Digiovanni J, Dannenberg AJ, et al. 2012. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev. Res. 5:1260-72
13. Xu XJ, Gauthier MS, Hess DT, et al. 2012. Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue. J. Lipid Res. 53:792-801
14. Kloting N, Fasshauer M, Dietrich A, et al. 2010. Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 299:E506-15
15. Denis GV, Obin MS. 2013. 'Metabolically healthy obesity': origins and implications. Mol. Aspects Med. 34:59-70
16. Chen S, Chen Y, Liu X, et al. 2014. Insulin resistance and metabolic syndrome in normal-weight individuals. Endocrine 46:496-504
17. Deepa M, Papita M, Nazir A, et al. 2014. Lean people with dysglycemia have a worse metabolic profile than centrally obese people without dysglycemia. Diabetes Technol. Ther. 16:91-96
18. LeeMJ, Wu Y, Fried SK. 2013. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol. Aspects Med. 34:1-11
19. Park J, Euhus DM, Scherer PE. 2011. Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr. Rev. 32:550-70
20. Khandekar MJ, Cohen P, Spiegelman BM. 2011. Molecular mechanisms of cancer development in obesity. Nat. Rev. Cancer 11:886-95
21. Pollak MN, Schernhammer ES, Hankinson SE. 2004. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4:505-18
22. Goodwin PJ, EnnisM, Pritchard KI, et al. 2002. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol. 20:42-51
23. Ma J, Li H, Giovannucci E, et al. 2008. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-Term survival analysis. Lancet Oncol. 9:1039-47
24. Barone BB, Yeh HC, Snyder CF, et al. 2008. Long-Term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-Analysis. JAMA 300:2754-64
25. Wong KK, Engelman JA, Cantley LC. 2010. Targeting the PI3K signaling pathway in cancer. Curr. Opin. Genet. Dev. 20:87-90
26. Zoncu R, Efeyan A, Sabatini DM. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12:21-35
27. Lueprasitsakul P, Latour D, Longcope C. 1990. Aromatase activity in human adipose tissue stromal cells: effect of growth factors. Steroids 55:540-44
28. Rosen ED, Spiegelman BM. 2014. What we talk about when we talk about fat. Cell 156:20-44
29. Hofbauer KG. 2002. Molecular pathways to obesity. Int. J. Obes. Relat.Metab.Disord. 26(Suppl. 2):S18-27
30. Alberti KG, Eckel RH, Grundy SM, et al. 2009. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640-45
31. Pothiwala P, Jain SK, Yaturu S. 2009. Metabolic syndrome and cancer. Metab. Syndr. Relat. Disord. 7:279-88
32. Capasso I, Esposito E, Pentimalli F, et al. 2010. Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol. Ther. 10:1240-43
33. Porto LA, Lora KJ, Soares JC, Costa LO. 2011. Metabolic syndrome is an independent risk factor for breast cancer. Arch. Gynecol. Obstet. 284:1271-76
34. Rosato V, Bosetti C, Talamini R, et al. 2011. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann. Oncol. 22:2687-92
35. Cleary MP, Grossmann ME. 2009. Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 150:2537-42
36. Reeves GK, Pirie K, Beral V, et al. 2007. Cancer incidence and mortality in relation to body mass index in the MillionWomen Study: cohort study. BMJ 335:1134-45
37. Li CI, Daling JR, Malone KE. 2003. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J. Clin. Oncol. 21:28-34
38. Key TJ, Appleby PN, Reeves GK, et al. 2003. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J. Natl. Cancer Inst. 95:1218-26
39. Lorincz AM, Sukumar S. 2006. Molecular links between obesity and breast cancer. Endocr. Relat. Cancer 13:279-92
40. Yager JD, Davidson NE. 2006. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354:270-82
41. Pequeux C, Raymond-Letron I, Blacher S, et al. 2012. Stromal estrogen receptor-Alpha promotes tumor growth by normalizing an increased angiogenesis. Cancer Res. 72:3010-19
42. Giovannucci E, Rimm EB, Liu Y, et al. 2003. Body mass index and risk of prostate cancer in U.S. health professionals. J. Natl. Cancer Inst. 95:1240-44
43. Jayachandran J, Banez LL, Aronson WJ, et al. 2009. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 115:5263-71
44. Parker AS, Thiel DD, Bergstralh E, et al. 2013. Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies. Prostate Cancer Prostatic Dis. 16:352-56
45. Lonergan PE, Tindall DJ. 2011. Androgen receptor signaling in prostate cancer development and progression. J. Carcinog. 10(20). doi: 10.4103/1477-3163.83937
46. Dhindsa S, MillerMG, McWhirter CL, et al. 2010. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 33:1186-92
47. Tilg H, Moschen AR. 2006. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6:772-83
48. HousaD, Housova J, Vernerova Z, Haluzik M. 2006. Adipocytokines and cancer. Physiol. Res. 55:233-44
49. Bub JD, Miyazaki T, Iwamoto Y. 2006. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem. Biophys. Res. Commun. 340:1158-66
50. Kim AY, Lee YS, KimKH, et al. 2010. Adiponectin represses colon cancer cell proliferation via AdipoR1-And-R2-mediated AMPK activation. Mol. Endocrinol. 24:1441-52
51. Cong L, Gasser J, Zhao J, et al. 2007. Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2. Endocr. Relat. Cancer 14:713-20
52. Grossmann ME, Nkhata KJ, Mizuno NK, et al. 2008. Effects of adiponectin on breast cancer cell growth and signaling. Br. J. Cancer 98:370-79
53. Sharma D, Wang J, Fu PP, et al. 2010. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 52:1713-22
54. Fogarty S, Hardie DG. 2010. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim. Biophys. Acta 1804:581-91
55. Lam JBB, Chow KHM, Xu A, et al. 2009. Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVTmice by modulation of phosphatase and tensin homolog activities. PLOS ONE 4(3):e4968
56. Miyoshi Y, Funahashi T, Kihara S, et al. 2003. Association of serum adiponectin levels with breast cancer risk. Clin. Cancer Res. 9:5699-70457.
57. DugganC, IrwinML, Xiao L, et al. 2011. Associations of insulin resistance and adiponectinwithmortality in women with breast cancer. J. Clin. Oncol. 29:32-39
58. MantzorosC, Petridou E, Dessypris N, et al. 2004. Adiponectin and breast cancer risk. J. Clin. Endocrinol. Metab. 89:1102-7
59. Soliman PT, Wu D, Tortolero-Luna G, et al. 2006. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 106:2376-81
60. Xu XT, Xu Q, Tong JL, et al. 2011. Meta-Analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J. Dig. Dis. 12:234-44
61. Michalakis K, Williams CJ, Mitsiades N, et al. 2007. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol. Biomark. Prev. 16:308-13
62. Li H, Stampfer MJ, Mucci L, et al. 2010. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin. Chem. 56:34-43
63. Friedman JM, Halaas JL. 1998. Leptin and the regulation of body weight in mammals. Nature 395:763-70
64. Sharma D, Saxena NK, Vertino PM, Anania FA. 2006. Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-Transduction pathways. Endocr. Relat. Cancer 13:629-40
65. Choi JH, Park SH, Leung PC, Choi KC. 2005. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-Activated protein kinases in ovarian cancer cells. J. Clin. Endocrinol. Metab. 90:207-10
66. Hoda MR, Keely SJ, Bertelsen LS, et al. 2007. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br. J. Surg. 94:346-54
67. Onuma M, Bub JD, Rummel TL, Iwamoto Y. 2003. Prostate cancer cell-Adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-Terminal kinase. J. Biol. Chem. 278:42660-67
68. Chia VM, Newcomb PA, Lampe JW, et al. 2007. Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. Cancer Epidemiol. Biomark. Prev. 16:2697-703
69. Grossmann ME, Mizuno NK, BonordenMJ, et al. 2009. Role of the adiponectin leptin ratio in prostate cancer. Oncol. Res. 18:269-77
70. Olefsky JM, Glass CK. 2010. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72:219-46
71. Pierce BL, Ballard-Barbash R, Bernstein L, et al. 2009. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J. Clin. Oncol. 27:3437-44
72. VisserM, Bouter LM, McQuillan GM, et al. 1999. Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131-35
73. Morris PG, Zhou XK, Milne GL, et al. 2013. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lungmetastases in patients with breast cancer. Cancer Prev. Res. 6:428-36
74. Kim S, Taylor JA, Milne GL, Sandler DP. 2013. Association between urinary prostaglandin E2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women. Cancer Prev. Res. 6:511-18
75. Amano SU, Cohen JL, Vangala P, et al. 2014. Local proliferation ofmacrophages contributes to obesityassociated adipose tissue inflammation. Cell Metab. 19:162-71
76. Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. 2013. Molecular pathways: adipose inflammation as a mediator of obesity-Associated cancer. Clin. Cancer Res. 19:6074-83
77. Mantovani A, Allavena P, Sica A, Balkwill F. 2008. Cancer-related inflammation. Nature 454:436-44
78. Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature 420:860-67
79. Osborn O, Olefsky JM. 2012. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 18:363-74
80. Monteiro R, Azevedo I. 2010. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm. 2010:1-10
81. Cinti S, Mitchell G, Barbatelli G, et al. 2005. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 46:2347-55
82. Subbaramaiah K, Howe LR, Bhardwaj P, et al. 2011. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev. Res. 4:329-46
83. Morris PG, Hudis CA, Giri D, et al. 2011. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev. Res. 4:1021-29
84. Sun X, Casbas-Hernandez P, Bigelow C, et al. 2012. Normal breast tissue of obese women is enriched for macrophage markers and macrophage-Associated gene expression. Breast Cancer Res. Treat. 131:1003-12
85. Bachelot T, Ray-Coquard I, Menetrier-CauxC, et al. 2003. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br. J. Cancer 88:1721-26
86. Subbaramaiah K, Morris PG, Zhou XK, et al. 2012. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov. 2:356-65
87. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. 1996. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137:5739-42
88. Irahara N, Miyoshi Y, Taguchi T, et al. 2006. Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-Alpha, IL-6 and COX-2 mRNAs in human breast cancer. Int. J. Cancer 118:1915-21
89. Shapiro H, Pecht T, Shaco-Levy R, et al. 2013. Adipose tissue foam cells are present in human obesity. J. Clin. Endocrinol. Metab. 98:1173-81
90. Underhill DM, Goodridge HS. 2012. Information processing during phagocytosis. Nat. Rev. Immunol. 12:492-502
91. Pendyala S, Walker JM, Holt PR. 2012. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 142:1100-01
92. Lee JY, Sohn KH, Rhee SH, Hwang D. 2001. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through toll-like receptor 4. J. Biol. Chem. 276:16683-89
93. Chlebowski RT, Blackburn GL, Thomson CA, et al. 2006. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J. Natl. Cancer Inst. 98:1767-76
94. Campbell KL, Foster-Schubert KE, AlfanoCM, et al. 2012. Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial. J. Clin. Oncol. 30:2314-26
95. Imayama I, Ulrich CM, AlfanoCM, et al. 2012. Effects of a caloric restrictionweight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Res. 72:2314-26
96. Ligibel JA, Goodwin PJ. 2012. NEW and RENEW: building the case for weight loss in breast cancer. J. Clin. Oncol. 30:2294-96
97. Goodwin PJ, Pritchard KI, Ennis M, et al. 2008. Insulin-lowering effects of metformin in women with early breast cancer. Clin. Breast Cancer 8:501-5
98. Dannenberg AJ, Altorki NK, Boyle JO, et al. 2001. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2:544-51
99. Higgins MJ, Prowell TM, Blackford AL, et al. 2012. A short-Term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res. Treat. 131:915-24
100. Hudis CA, Subbaramaiah K, Morris PG, Dannenberg AJ. 2012. Breast cancer risk reduction: no pain, no gain?. J. Clin. Oncol. 30:3436-38